DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cas No.: | 171500-79-1 |
| Chemical Name: | Dalbavacin |
| Synonyms: | Dalbavacin;Dalbavancin;BI-397;MDL-63397;MDL 63397;Dalbavancin(BI 397, MDL 63397);A-A-1, Dalbavancin Ao, BI 397, MDL 63397;5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-β-D-glucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-α-D-mannopyranosyl-N15-methyl-Ristomy |
| SMILES: | CN[C@H]1C(N[C@@H]2Cc3ccc(Oc4c(O[C@@H]5O[C@H](C(O)=O)[C@H]([C@@H]([C@H]5NC(CCCCCCCCC(C)C)=O)O)O)c(Oc6c(Cl)cc([C@H]([C@@H]7NC([C@@H](c8cc(c9c([C@@H](C(NCCCN(C)C)=O)NC7=O)cc(O)cc9O[C@H]%10O[C@@H]([C@H]([C@@H]([C@@H]%10O)O)O)CO)c(O)cc8)NC([C@@H]%11NC([C@H](c%12c(Cl)c(O)cc(Oc%13c(O)ccc1c%13)c%12)NC2=O)=O)=O)=O)O)cc6)cc%11c4)cc3)=O |
| Formula: | C88H100N10O28Cl2 |
| M.Wt: | 1816.6918 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Dalbavancin is a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens. |
| In Vivo: | Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1]. Animal Model: Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis[1] Dosage: 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg Administration: Intraperitoneal injection; every 36 h or 72 h; for 14 days Result: The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. |
| In Vitro: | Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|